newsfilter
← Latest News
Business Wire·

Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months

Second Patient Completed Treatment and Third Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company")